Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

We investigated >= grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The...

Descripción completa

Detalles Bibliográficos
Autores: Penack, Olaf, Peczynski, Christophe, Koenecke, Christian, Polge, Emmanuelle, Sanderson, Robin, Yakoub Agha, Ibrahim, Fegueux, Nathalie, Daskalakis, Michael, Collin, Matthew, Dreger, Peter, Kröger, Nicolaus, Schanz, Urs, Bloor, Adrian, Ganser, Arnold, Besley, Caroline, Wulf, Gerald G., Novak, Urban, Moiseev, Ivan, Schoemans, Hélène, Basak, Grzegorz W., Chabannon, Christian, Sureda, Anna, Glass, Bertram, Peric, Zinaida
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/208421
Acceso en línea:https://hdl.handle.net/2445/208421
Access Level:acceso abierto
Palabra clave:Limfomes
Receptors cel·lulars
Lymphomas
Cell receptors
Descripción
Sumario:We investigated >= grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of >= grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.

Similares en LA Referencia